You are here: Industry Insights > Shionogi

News List

Akili, Shionogi to develop digital therapeutics in key Asian markets biospectrumasia
March 11, 2019
Akili Interactive and Shionogi & Co. have announced that they have entered into a strategic partnership for the commercialization of Akili’s digital medicines, AKL-T01 and AKL-T02, in Japan and Taiwan, China region in China.
Shionogi receives Marketing Authorisation for Rizmoic (naldemedine) for the treatment of opioid-induced constipation in adults firstwordpharma
February 24, 2019
Shionogi & Co., Ltd. (hereafter "Shionogi"), a research-driven pharmaceutical company, announced today thatthe European Commission(EC) has granted Marketing Authorisation(MA) for Rizmoic® (naldemedine), for the treatment of opioid-induced constipation (OI
PeptiDream and Shionogi sign peptide drug conjugate discovery deal pharmaceutical-technology
January 24, 2019
PeptiDream has signed a deal with fellow Japanese pharmaceutical company Shionogi to discover and develop a series of blood-brain barrier (BBB) penetrating peptide drug conjugates.
Shionogi submits NDA for INTUNIV biospectrumasia
August 22, 2018
Shire’s partner, Shionogi, filed application to expand INTUNIV indication in Japan to include adults with ADHD.
Shionogi's thrombocytopenia drug granted 'priority review' by the US FDA biospectrumasia
February 27, 2018
The drug has already bagged the Japanese approval in September 2015 for the improvement of thrombocytopenia associated with chronic liver disease
Shionogi Announces Positive Top-Line Results for Cefiderocol Pivotal cUTI Clinical Trial americanpharmaceuticalreview
January 13, 2017
Shionogi & Co. has announced that cefiderocol (S-649266), a novel siderophore cephalosporin in late-stage development, met the FDA pre-specified primary endpoint for non-inferiority vs imipenem/cilastatin (IPM/CS) in patients with serious complicated urin

Previous page 1 2 Next page